The mutational landscape of pancreatic and liver cancer, as represented by circulating tumour DNA
File(s)fonc-09-00952.pdf (4.7 MB)
Published version
Author(s)
Rice, alistair
Del Rio Hernandez, Armando
Type
Journal Article
Abstract
The mutational landscapes of pancreatic and liver cancer share many common genetic alterations which drive cancer progression.
However, these mutations do not occur in all cases of these diseases, and this tumoural heterogeneity impedes diagnosis,
prognosis and therapeutic development. One minimally invasive method for the evaluation of tumour mutations is the analysis of
circulating tumour DNA (ctDNA), released through apoptosis, necrosis and active secretion by tumour cells into various body fluids.
By observing mutations in those genes which promote transformation by controlling the cell cycle and oncogenic signalling
pathways, a representation of the mutational profile of the tumour is revealed. The analysis of ctDNA is a promising technique for
investigating these two gastrointestinal cancers, as many studies have reported on the accuracy of ctDNA assessment for
diagnosis and prognosis using a variety of techniques.
However, these mutations do not occur in all cases of these diseases, and this tumoural heterogeneity impedes diagnosis,
prognosis and therapeutic development. One minimally invasive method for the evaluation of tumour mutations is the analysis of
circulating tumour DNA (ctDNA), released through apoptosis, necrosis and active secretion by tumour cells into various body fluids.
By observing mutations in those genes which promote transformation by controlling the cell cycle and oncogenic signalling
pathways, a representation of the mutational profile of the tumour is revealed. The analysis of ctDNA is a promising technique for
investigating these two gastrointestinal cancers, as many studies have reported on the accuracy of ctDNA assessment for
diagnosis and prognosis using a variety of techniques.
Date Issued
2019-09-24
Date Acceptance
2019-09-09
Citation
Frontiers in Oncology, 2019, 9
ISSN
2234-943X
Publisher
Frontiers Media
Journal / Book Title
Frontiers in Oncology
Volume
9
Copyright Statement
© 2019 Rice and del Rio Hernandez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Sponsor
Commission of the European Communities
Imperial Confident in Concept - NIHR Imperial BRC Therapeutic Primer Funds
Commission of the European Communities
Grant Number
282051
Imperial Confident in Concept - NIHR Imperial BRC Therapeutic Primer Funds
780360
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
circulating tumor DNA (ctDNA)
pancreatic ductal adenocarcinoma (PDAC)
hepatocellular cancer (HCC)
somatic mutations in cancer
tumor heterogeneity
CELL-FREE-DNA
HEPATOCELLULAR-CARCINOMA PATIENTS
ABERRANT PROMOTER METHYLATION
249(SER) P53 MUTATION
K-RAS MUTATIONS
COPY NUMBER
PLASMA DNA
GENETIC ALTERATIONS
QUANTITATIVE-ANALYSIS
HIGH-FREQUENCY
1112 Oncology and Carcinogenesis
Publication Status
Published
Article Number
ARTN 952